International Journal of Thyroidology

Table. 1.

Table. 1.

Relationship between PHGDH expression and clinicopathologic factors in patients with thyroid cancer (n=230)

Variable Number of patients PHGDH expression

Negative (n=56) Positive (n=174) p-value
Age, years 50.2±14.6 51.5±16.4 0.417
Sex Male 55 16 (29.1) 39 (70.9) 0.746
Female 175 40 (22.9) 135 (77.1)
Tumor size <2 cm 93 30 (32.3) 63 (67.7) 0.021
≥2 cm 137 26 (19.0) 111 (81.0)
ETE No 76 24 (31.6) 52 (68.4) 0.073
Yes 154 32 (20.8) 122 (79.2)
Central LNM No 95 39 (41.1) 56 (58.9) 0.001
Yes 135 17 (12.6) 118 (87.4)
Lateral LNM No 179 51 (28.5) 128 (71.5) 0.006
Yes 51 5 (9.8) 46 (90.2)
LVI No 53 17 (32.1) 36 (67.9) 0.135
Yes 177 39 (22.0) 138 (78.0)
Recurrence No 193 52 (26.9) 141 (73.1) 0.036
Yes 37 4 (10.8) 33 (89.2)
GLUT1 expression Low 166 48 (28.9) 118 (71.1) 0.009
High 64 8 (12.5) 56 (87.5)

Data are presented as n (%) or mean±standard deviation unless otherwise noted. p-values were obtained from unpaired t-tests for continuous parametric variables and the Mann–Whitney U test for nonparametric variables. The chi-squared test and Fisher’s exact test were used to evaluate the significance of the correlations of PHGDH expression with clinical and pathological parameters. AJCC: American Joint Committee on Cancer, GLUT1: glucose transporter 1, ETE: extrathyroidal extension, LNM: lymph node metastasis, LVI: lymphovascular invasion, PHGDH: phosphoglycerate dehydrogenase

Int J Thyroidol 2023;16:175-83 https://doi.org/10.11106/ijt.2023.16.2.175
© 2023 Int J Thyroidol